SVB Securities analyst Andrew Berens maintained a Buy rating on Tango Therapeutics (TNGX – Research Report) on May 9 and set a price target of $16.00. The company’s shares opened today at $3.82.
Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Incyte, and Zentalis Pharmaceuticals. According to TipRanks, Berens has an average return of 1.5% and a 47.12% success rate on recommended stocks.
Tango Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.75, implying a 312.30% upside from current levels. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $8.56 and a one-year low of $3.10. Currently, Tango Therapeutics has an average volume of 192.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BCTG Acquisition Corp is a blank check company.
Read More on TNGX:
- Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights
- TNGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
- Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers
- Tango Therapeutics announces FDA clearance of IND application for TNG260
